The invention describes a peptide vaccine which aims at cancers. Particularly, the invention provides isolated epitope peptides which derive from an SEMA5B gene and leads to CTL, and therefore the isolated epitope peptides are suitable for immunotherapy on cancers. Each peptide of the invention comprises an SEMA5B derived peptide and a modified form thereof, wherein one, two or a plurality of amino acids are substituted, missing, inserted or added as long as the modified forms have the necessary CTL induction capability of the original sequence. Furthermore the invention provides a polynucleotide for coding the peptides, and a drug composition comprising a random peptide or the polynucleotide as active reagents. The invention further provides an antigen presenting cell which is targeted to the peptides and an isolated CTL, and a method for inducing the antigen presenting cell or the CTL. Furthermore the invention provides a method for treating and/or preventing (such as preventing) cancer (tumor)(such as esophageal cancer, NSCLC, RCC and SCLC) and/or preventing cancer metastasis or reoccurrence after surgery, a method for inducing the CTL, and a method for inducing an anti-tumor immunity, wherein the peptides which derive from the SEMA5B, the polynucleotide for coding the peptides or the antigen presenting cell for presenting the peptides, or the drug composition are represented.
